{"id":9208,"date":"2020-04-27T19:28:46","date_gmt":"2020-04-27T13:58:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9208"},"modified":"2024-09-18T13:19:16","modified_gmt":"2024-09-18T07:49:16","slug":"chemotherapy-induced-febrile-neutropenia-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market","title":{"rendered":"Chemotherapy Induced Febrile Neutropenia Market: High time to end the monopoly"},"content":{"rendered":"\n

A rich pipeline in the Chemotherapy Induced Febrile Neutropenia market with promising clinical pieces of evidence, CIFN market size is expected to increase drastically by 2030 <\/strong><\/em><\/p>\n\n\n\n

A range of breakthroughs and series of medical advancements have significantly helped in dampening down the global burden of cancer, which as per a report by WHO was estimated to be 18.1 million new cases and 9.6 million deaths in 2018. Improved diagnosis, testing and awareness have facilitated early detection of cancer and targeting cancer through surgery, radiation therapy, chemotherapy and immunotherapy<\/a> have overall increased survival rate, and life expectancy of the cancer<\/a> patients. <\/p>\n\n\n\n

However, with the inclination towards cytotoxic\napproaches to target and kill cancer, several complications arise such as\nkilling or destroying neutrophils or white blood cells. Neutropenia is one of\nthe most severe hematologic toxicities of cancer<\/a>\nchemotherapy and often limits the doses of chemotherapy tolerated by the\npatients. It is a condition that results in a low neutrophil count in the blood,\nthus rendering the patient susceptible to infections from pathogens, ultimately\nleading to fever \u2013 in the case known as Chemotherapy Induced Febrile Neutropenia<\/strong>\n(CIFN). <\/p>\n\n\n\n

Febrile neutropenia is one of the most common and adverse complications of chemotherapy, which in addition to reduced immunity, also delays the course of treatments, leads to early termination of the doses, and compromises with the potential of curing the patient. It is often associated with increased treatment cost, morbidity and mortality. <\/p>\n\n\n\n

Chemotherapy Induced Febrile Neutropenia Market:\nMarketed therapies <\/strong><\/h2>\n\n\n\n

A result of chemotherapy \u2013 often myelosuppressive\n\u2013 the condition calls for urgent evaluation, and monitoring. The current\nstandard of care in Chemotherapy Induced Febrile Neutropenia market is granulocytic\ncolony-stimulating factor<\/strong> (G-CSF). In the U.S. and Europe, G-CSF is being\nused prophylactically only in high-risk patients and as a therapeutic once\nneutropenia is detected. <\/p>\n\n\n\n

The first and only approved human G-CSF – Neupogen<\/strong>\n(Filgrastim) \u2013 an Amgen\u2019s product \u2013 is a leukocyte growth factor indicated to\ndecrease the occurrence of infection\u201a reduce the time to neutrophil recovery\nand the duration of fever, following induction or consolidation chemotherapy\ntreatment of patients with acute myeloid leukemia (AML). When Neupogen first\nentered the market in 1991, it proved to be a blockbuster and managed to\ndominate Chemotherapy Induced Febrile\nNeutropenia market even with high prices and a few limitations. The patent\nexpiry of Neupogen paved the way for biosimilars to have their fair share of\nCIFN market. <\/p>\n\n\n\n

Zarxio<\/strong> by Sandoz became\nthe first approved biosimilar in 2009 in E.U. and in 2015 in the U.S. The\nbiosimilar is a leukocyte growth factor indicated to decrease the incidence of\ninfection and reduce the time to neutrophil recovery and the duration of fever.\nSince its launch, Zarxio has posed to be a fierce competition to Neupogen. However,\nthe launch of   Neulasta <\/strong>by Amgen again turned the tables,\nowing to its administration once-during the chemotherapy cycle. Other marketed\ntherapies in the Chemotherapy\nInduced Febrile Neutropenia market are Teva\u2019s Granix<\/strong> in U.S. and Lonquex<\/strong>\nin other parts of the world.<\/p>\n\n\n\n

However, G-CSF treatments did not prove\nto be 100% effective with associated side effects such as splenic rupture, severe\nbone pain, chest pain, nausea, hypoxemia, and they were not pocket friendly either.\nMoreover, they are administered after 1-3 days of chemotherapy; if administered\nthe same day, it may worsen neutropenia. <\/p>\n\n\n\n

Chemotherapy Induced Febrile Neutropenia Market:\nUnmet needs and R&D in the space <\/strong><\/h2>\n\n\n\n

The current limitations of the\ntreatments and therapies have led doctors and physicians to hunt for the alternatives\nto existing therapies with the help of extensive R&D in the domain. The therapeutics\nin the Chemotherapy Induced Febrile\nNeutropenia pipeline is mostly biosimilars of G-CSF or antibiotics that differ\nin their mechanisms and approaches to treat CIFN in several aspects, hence have\nthe edge over the marketed ones. <\/p>\n\n\n\n

Rolontis (Spectrum\nPharmaceuticals), Fulphila (Mylan Pharmaceuticals), Udenyca (Coherus\nBiosciences), Mosedipimod (Enzychem), Pelmeg (Cinfa Biotech S.L.), Ziextenzo (Sandoz\nPharmaceuticals), Myelo001 (Myelo Therapeutics), ALRN-6924 (Aileron\nTherapeutics) along with Neulasta biosimilars including MYL-1401H (Mylan\nPharmaceuticals), CHS-1701 (Coherus Biosciences), B12109 (Cinfa Biotech S.L.)\nand LA-EP2006 (Sandoz Pharmaceuticals) are anticipated to impact Chemotherapy Induced Febrile Neutropenia\nmarket positively. <\/p>\n\n\n\n

In addition to Spectrum Pharmaceuticals, Mylan Pharmaceuticals, Coherus Biosciences, Enzychem, Cinfa Biotech, Sandoz Pharmaceuticals, Myelo Therapeutics, Aileron Therapeutics, Mylan Pharmaceuticals, other pharma companies such as Generon Corporation, and USV Biologics are also investing their funds and time in developing an effective cure to address the unmet needs in the Chemotherapy Induced Febrile Neutropenia market. <\/p>\n\n\n\n

\"Chemotherapy
Chemotherapy Induced Febrile Neutropenia market<\/a><\/strong> <\/figcaption><\/figure>\n\n\n\n

A rich pipeline in the Chemotherapy\nInduced Febrile Neutropenia market<\/a><\/strong> with promising clinical pieces of evidence, CIFN\nmarket size is expected to increase drastically by 2030. The emerging drugs are\ngoing to grab the share, thus ending the monopoly of Neulasta in the CIFN\nmarket. As per DelveInsight, CIFN market will witness the entry of several\npotential drugs that will cut down the share of Neulasta and deteriorate its\nearnings. <\/p>\n\n\n\n

Overall, a robust pipeline filled with novel therapies along with the rising prevalence of the disease will lead to a significant boost to the Chemotherapy Induced Febrile Neutropenia market revenue generated during the forecast period [2020-2030].<\/p>\n\n\n\n

What is Chemotherapy Induced Febrile Neutropenia? <\/strong>

Febrile neutropenia is one of the most common and adverse complications of chemotherapy that results in reduced immunity, delayed course of treatment, early termination of the doses, increased treatment cost, morbidity and mortality.<\/p> <\/div>

What are the pipeline products in the Chemotherapy Induced Febrile Neutropenia Market?<\/strong>

Rolontis, Fulphila, Udenyca, Mosedipimod, Pelmeg, Ziextenzo, Myelo001, ALRN-6924, MYL-1401H, CHS-1701, B12109 and LA-EP2006 are anticipated to impact Chemotherapy Induced Febrile Neutropenia market positively.<\/p> <\/div>

What are the key companies in the Chemotherapy Induced Febrile Neutropenia Market? <\/strong>

Spectrum Pharmaceuticals, Mylan Pharmaceuticals, Coherus Biosciences, Enzychem, Cinfa Biotech, Sandoz Pharmaceuticals, Myelo Therapeutics, Aileron Therapeutics, Mylan Pharmaceuticals, Generon Corporation, and USV Biologics are the key companies in the CIFN market. <\/p> <\/div>

What are the unmet needs in the CIFN market? <\/strong>

The current limitations of the treatments including not 100% effective, associated side effects such as splenic rupture, severe bone pain, chest pain, nausea, hypoxemia, affordability, and administration duration are the major unmet needs in the CIFN market. <\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"

A rich pipeline in the Chemotherapy Induced Febrile Neutropenia market with promising clinical pieces of evidence, CIFN market size is expected to increase drastically by 2030 A range of breakthroughs and series of medical advancements have significantly helped in dampening down the global burden of cancer, which as per a report by WHO was estimated […]<\/p>\n","protected":false},"author":1,"featured_media":9229,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[18275,18274,18269,18266,18267,18264,2045,18273,18272,413,18261,18268,18262,18271,18263,18265,18270],"industry":[17225],"therapeutic_areas":[18276],"class_list":["post-9208","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-aileron-therapeutics","tag-alrn-6924","tag-cinfa-biotech-s-l","tag-coherus-biosciences","tag-enzychem","tag-fulphila","tag-mosedipimod","tag-myelo-therapeutics","tag-myelo001","tag-mylan-pharmaceuticals","tag-neupogen","tag-pelmeg","tag-rolontis","tag-sandoz-pharmaceuticals","tag-spectrum-pharmaceuticals","tag-udenyca","tag-ziextenzo","industry-pharmaceutical","therapeutic_areas-toxicology"],"acf":[],"yoast_head":"\nChemotherapy Induced Febrile Neutropenia Market | CIFN Market<\/title>\n<meta name=\"description\" content=\"Chemotherapy Induced Febrile Neutropenia market is anticipated to grow due to a rich pipeline in the CIFN market, rising cancer prevalence, increased R&D...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chemotherapy Induced Febrile Neutropenia Market | CIFN Market\" \/>\n<meta property=\"og:description\" content=\"Chemotherapy Induced Febrile Neutropenia market is anticipated to grow due to a rich pipeline in the CIFN market, rising cancer prevalence, increased R&D...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-27T13:58:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:49:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chemotherapy Induced Febrile Neutropenia Market | CIFN Market","description":"Chemotherapy Induced Febrile Neutropenia market is anticipated to grow due to a rich pipeline in the CIFN market, rising cancer prevalence, increased R&D...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market","og_locale":"en_US","og_type":"article","og_title":"Chemotherapy Induced Febrile Neutropenia Market | CIFN Market","og_description":"Chemotherapy Induced Febrile Neutropenia market is anticipated to grow due to a rich pipeline in the CIFN market, rising cancer prevalence, increased R&D...","og_url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-27T13:58:46+00:00","article_modified_time":"2024-09-18T07:49:16+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market","url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market","name":"Chemotherapy Induced Febrile Neutropenia Market | CIFN Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market.png","datePublished":"2020-04-27T13:58:46+00:00","dateModified":"2024-09-18T07:49:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Chemotherapy Induced Febrile Neutropenia market is anticipated to grow due to a rich pipeline in the CIFN market, rising cancer prevalence, increased R&D...","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587976324217"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977304383"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977338762"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977385661"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market.png","width":772,"height":482,"caption":"Chemotherapy Induced Febrile Neutropenia Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587976324217","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587976324217","name":"What is Chemotherapy Induced Febrile Neutropenia?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Febrile neutropenia is one of the most common and adverse complications of chemotherapy that results in reduced immunity, delayed course of treatment, early termination of the doses, increased treatment cost, morbidity and mortality.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977304383","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977304383","name":"What are the pipeline products in the Chemotherapy Induced Febrile Neutropenia Market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Rolontis, Fulphila, Udenyca, Mosedipimod, Pelmeg, Ziextenzo, Myelo001, ALRN-6924, MYL-1401H, CHS-1701, B12109 and LA-EP2006 are anticipated to impact Chemotherapy Induced Febrile Neutropenia market positively.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977338762","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977338762","name":"What are the key companies in the Chemotherapy Induced Febrile Neutropenia Market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Spectrum Pharmaceuticals, Mylan Pharmaceuticals, Coherus Biosciences, Enzychem, Cinfa Biotech, Sandoz Pharmaceuticals, Myelo Therapeutics, Aileron Therapeutics, Mylan Pharmaceuticals, Generon Corporation, and USV Biologics are the key companies in the CIFN market. ","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977385661","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/chemotherapy-induced-febrile-neutropenia-market#faq-question-1587977385661","name":"What are the unmet needs in the CIFN market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The current limitations of the treatments including not 100% effective, associated side effects such as splenic rupture, severe bone pain, chest pain, nausea, hypoxemia, affordability, and administration duration are the major unmet needs in the CIFN market. ","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/27192759\/Chemotherapy-Induced-Febrile-Neutropenia-Market-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Aileron Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">ALRN-6924<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Cinfa Biotech S.L.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Coherus Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Enzychem<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fulphila<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Mosedipimod<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Myelo Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Myelo001<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Mylan Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Neupogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pelmeg<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Rolontis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Sandoz Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Spectrum Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Udenyca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Ziextenzo<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aileron Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">ALRN-6924<\/span>","<span class=\"advgb-post-tax-term\">Cinfa Biotech S.L.<\/span>","<span class=\"advgb-post-tax-term\">Coherus Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Enzychem<\/span>","<span class=\"advgb-post-tax-term\">Fulphila<\/span>","<span class=\"advgb-post-tax-term\">Mosedipimod<\/span>","<span class=\"advgb-post-tax-term\">Myelo Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Myelo001<\/span>","<span class=\"advgb-post-tax-term\">Mylan Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Neupogen<\/span>","<span class=\"advgb-post-tax-term\">Pelmeg<\/span>","<span class=\"advgb-post-tax-term\">Rolontis<\/span>","<span class=\"advgb-post-tax-term\">Sandoz Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Spectrum Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Udenyca<\/span>","<span class=\"advgb-post-tax-term\">Ziextenzo<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 27, 2020","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Apr 27, 2020 7:28 pm","modified":"Updated on Sep 18, 2024 1:19 pm"},"featured_img_caption":"Chemotherapy Induced Febrile Neutropenia Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9208"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9208\/revisions"}],"predecessor-version":[{"id":29594,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9208\/revisions\/29594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9229"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9208"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9208"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}